{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:40:18Z","timestamp":1654562418330},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,3,4]],"date-time":"2016-03-04T00:00:00Z","timestamp":1457049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,3,4]],"date-time":"2016-03-04T00:00:00Z","timestamp":1457049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl."],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00103-016-2319-6","type":"journal-article","created":{"date-parts":[[2016,3,4]],"date-time":"2016-03-04T13:59:54Z","timestamp":1457099994000},"page":"482-488","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vom Kompetenznetz Hepatitis (HepNet) zur Deutschen Leberstiftung"],"prefix":"10.1007","volume":"59","author":[{"given":"S.","family":"Hardtke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Wiebner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,4]]},"reference":[{"issue":"7","key":"2319_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1055\/s-0031-1273462","volume":"49","author":"M Cornberg","year":"2011","unstructured":"Cornberg M et al (2011) Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection \u2013 The German Guideline. Z Gastroenterol 49(7):871\u2013930","journal-title":"Z Gastroenterol"},{"issue":"4","key":"2319_CR2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa0912696","volume":"364","author":"H Wedemeyer","year":"2011","unstructured":"Wedemeyer H et al (2011) Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364(4):322\u2013331","journal-title":"N Engl J Med"},{"issue":"203a","key":"2319_CR3","first-page":"202a","volume":"56","author":"C Yurdaydin","year":"2012","unstructured":"Yurdaydin C et al (2012) Pegylated-interferon-a-2a plus Tenofovir or placebo for the treatment of hepatitis delta: first results of the HIDIT-2 study. Hepatology 56(203a):202a","journal-title":"Hepatology"},{"issue":"20","key":"2319_CR4","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1056\/NEJMoa011232","volume":"345","author":"E Jaeckel","year":"2001","unstructured":"Jaeckel E et al (2001) Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345(20):1452\u20131457","journal-title":"N Engl J Med"},{"issue":"2","key":"2319_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/hep.21043","volume":"43","author":"J Wiegand","year":"2006","unstructured":"Wiegand J et al (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43(2):250\u2013256","journal-title":"Hepatology"},{"issue":"6","key":"2319_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1473-3099(13)70059-8","volume":"13","author":"K Deterding","year":"2013","unstructured":"Deterding K et al (2013) Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 13(6):497\u2013506","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2319_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1055\/s-0028-1110008","volume":"48","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C et al (2010) Prophylaxis, Diagnosis and Therapy of Hepatitis C Virus (HCV) Infection: The German Guidelines on the Management of HCV Infection. Z Gastroenterol 48(2):289\u2013351","journal-title":"Z Gastroenterol"},{"issue":"3","key":"2319_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/MEG.0b013e32832c7b2e","volume":"22","author":"CM Dintsios","year":"2010","unstructured":"Dintsios CM et al (2010) Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. Eur J Gastroenterol Hepatol 22(3):278\u2013288","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"2319_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1086\/600058","volume":"49","author":"M Vogel","year":"2009","unstructured":"Vogel M et al (2009) Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large german networks on the study of acute HCV infection. Clin Infect Dis 49(2):317\u2013319. doi:10.1086\/600058","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2319_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1055\/s-0028-1109149","volume":"47","author":"K Deterding","year":"2009","unstructured":"Deterding K et al (2009) The german hep-net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 47(6):531\u2013540","journal-title":"Z Gastroenterol"},{"issue":"3","key":"2319_CR11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/135965350701200306","volume":"12","author":"J Wiegand","year":"2007","unstructured":"Wiegand J et al (2007) Fate and function of hepatitis-C-virus-specific T\u2011cells during peginterferon-alpha 2b therapy for acute hepatitis C. Antivir Ther (Lond) 12(3):303\u2013316","journal-title":"Antivir. Ther. (Lond.)"},{"issue":"2","key":"2319_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/hep.21043","volume":"43","author":"J Wiegand","year":"2006","unstructured":"Wiegand J et al (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET Acute-HCV-II Study. Hepatology 43(2):250\u2013256","journal-title":"Hepatology"},{"issue":"1","key":"2319_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.20291","volume":"40","author":"J Wiegand","year":"2004","unstructured":"Wiegand J et al (2004) Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 40(1):98\u2013107","journal-title":"Hepatology"},{"key":"2319_CR14","doi-asserted-by":"publisher","first-page":"840a","DOI":"10.1016\/j.jhep.2011.11.016","volume":"56","author":"M Friedrich-Rust","year":"2012","unstructured":"Friedrich-Rust M et al (2012) Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C. Hepatology 56:840a","journal-title":"Hepatology"},{"issue":"1","key":"2319_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/hep.26644","volume":"59","author":"M Wiese","year":"2014","unstructured":"Wiese M et al (2014) Evaluation of liver disease progression in the german hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology 59(1):49\u201357","journal-title":"Hepatology"},{"issue":"1","key":"2319_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hep.27102","volume":"60","author":"B Heidrich","year":"2014","unstructured":"Heidrich B et al (2014) Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 60(1):87\u201397","journal-title":"Hepatology"},{"issue":"5","key":"2319_CR17","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1053\/j.gastro.2011.07.019","volume":"141","author":"C Sarrazin","year":"2011","unstructured":"Sarrazin C et al (2011) Improved responses to Pegylated interferon alfa-2b and Ribavirin by individualizing treatment for 24\u201372 weeks. Gastroenterology 141(5):1656\u20131664","journal-title":"Gastroenterology"},{"issue":"2","key":"2319_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/hep.22991","volume":"50","author":"T Berg","year":"2009","unstructured":"Berg T et al (2009) Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1\u2011infected patients. Hepatology 50(2):369\u2013377","journal-title":"Hepatology"},{"issue":"10","key":"2319_CR19","doi-asserted-by":"publisher","first-page":"p. e108751","DOI":"10.1371\/journal.pone.0108751","volume":"9","author":"B Heidrich","year":"2014","unstructured":"Heidrich B et al (2014) reatment of naive patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. PloS One 9(10):p. e108751","journal-title":"PloS One"},{"issue":"5","key":"2319_CR20","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/hep.22483","volume":"48","author":"M von Wagner","year":"2008","unstructured":"von Wagner M et al (2008) Placebo-controlled trial of 400\u202fmg amantadine combined with peginterferon alfa-2a and ribavirin for 48\u00a0weeks in chronic hepatitis C virus-1 infection. Hepatology 48(5):1404\u20131411","journal-title":"Hepatology"},{"issue":"8","key":"2319_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nrd4050","volume":"12","author":"MP Manns","year":"2013","unstructured":"Manns MP, von Hahn T (2013) Novel therapies for hepatitis C \u2013 one pill fits all? Nat Rev Drug Discov 12(8):595\u2013610","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2319_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S1473-3099(13)70074-4","volume":"13","author":"MP Manns","year":"2013","unstructured":"Manns MP, Cornberg M (2013) Sofosbuvir: the final nail in the coffin for hepatitis C? Lancet Infect Dis 13(5):378\u2013379","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 1","key":"2319_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/jvh.12249","volume":"21","author":"H Wedemeyer","year":"2014","unstructured":"Wedemeyer H et al (2014) Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 21(Suppl 1):60\u201389","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"2319_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jvh.12248","volume":"21","author":"H Razavi","year":"2014","unstructured":"Razavi H et al (2014) The present and future disease burden of hepatitis C virus (HCV) infection with today\u2019s treatment paradigm. J Viral Hepat 21(Suppl 1):34\u201359","journal-title":"J Viral Hepat"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-016-2319-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00103-016-2319-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-016-2319-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-016-2319-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:03:08Z","timestamp":1654560188000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00103-016-2319-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["2319"],"URL":"https:\/\/doi.org\/10.1007\/s00103-016-2319-6","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,4]]},"assertion":[{"value":"4 March 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Hardtke und B.\u00a0Wiebner geben an, dass kein Interessenkonflikt besteht. M.P.\u00a0Manns: Beratert\u00e4tigkeit, Forschungsunterst\u00fctzung, Studienteilnahme oder Vortragshonorare von: AbbVie, Achillion, Biotest, Bristol-Myers-Squibb, Boehringer Ingelheim, Eiger Pharmaceuticals, Falk Pharma, Gilead Sciences, GlaxoSmithKline, Intercept, Janssen, Merck\/MSD, Novartis, Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}